Search Results - "Nonomiya, Yuma"
-
1
Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway
Published in Biochemical and biophysical research communications (19-03-2019)“…Poly (ADP-ribose) polymerases (PARPs) are involved in various cellular events, including DNA repair. PARP inhibitors including olaparib and rucaparib, have…”
Get full text
Journal Article -
2
Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study
Published in Biological & pharmaceutical bulletin (10-02-2024)“…Trastuzumab deruxtecan (T-DXd) has displayed demonstrable efficacy and manageable toxicity in previously treated patients with advanced gastric and breast…”
Get full text
Journal Article -
3
Effect of AKT3 expression on MYC‐ and caspase‐8‐dependent apoptosis caused by polo‐like kinase inhibitors in HCT 116 cells
Published in Cancer science (01-12-2016)“…Polo‐like kinase (PLK) is a cell‐cycle regulator that is overexpressed in several cancer cell types. Polo‐like kinase is considered a novel target for cancer…”
Get full text
Journal Article -
4
Functional Effects of AKT3 on Aurora Kinase Inhibitor-induced Aneuploidy
Published in The Journal of biological chemistry (03-02-2017)“…The suppression of mitotic Aurora kinases (AURKs) by AURK inhibitors frequently causes cytokinetic failure, leading to polyploidy or aneuploidy, indicating the…”
Get full text
Journal Article -
5
Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands
Published in Oncology research (07-05-2019)“…Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side…”
Get full text
Journal Article -
6
Effect of AKT 3 expression on MYC ‐ and caspase‐8‐dependent apoptosis caused by polo‐like kinase inhibitors in HCT 116 cells
Published in Cancer science (01-12-2016)“…Polo‐like kinase ( PLK ) is a cell‐cycle regulator that is overexpressed in several cancer cell types. Polo‐like kinase is considered a novel target for cancer…”
Get full text
Journal Article